Zhejiang Zhenyuan Expects Approval For Hepatobiliary Drug
This article was originally published in PharmAsia News
Executive Summary
Zhejiang Zhenyuan said it expects regulatory approval for its new hepatobiliary drug, succinic acid SAM APIs and injections, after finishing a review.